Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
- 30 April 2004
- journal article
- clinical trial
- Published by Elsevier in Clinical Immunology
- Vol. 111 (1) , 28-37
- https://doi.org/10.1016/j.clim.2004.01.006
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgarisJournal of Clinical Investigation, 1999
- In situ expression of B7 and CD28 receptor families in skin lesions of patients with lupus erythematosusArthritis & Rheumatism, 1997
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory moleculeEuropean Journal of Immunology, 1995
- B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapyCell, 1995
- “Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4Nature Biotechnology, 1992
- Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques.The Journal of Experimental Medicine, 1986
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978
- A Theory of Self-Nonself DiscriminationScience, 1970